ISPOR Announces Plenary Sessions and Speakers For 22nd Annual International Meeting

Published Mar 6, 2017

Conference to Focus on Timely Theme of Evidence and Value in a Time of Social and Policy Change

Princeton, NJ—March 6, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced plenary sessions and speakers for its 22nd Annual International Meeting that will be held May 20-24, 2017 in Boston, MA, USA. The conference will focus on significant changes in health care and policy with the timely theme, Evidence and Value in a Time of Social and Policy Change. Conference Co-Chairs are William H. Crown, PhD, Chief Scientific Officer, OptumLabs, Boston, MA, USA and Peter J. Neumann, ScD, Professor and Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. The first plenary session, Where Is US Health Policy Going?, is scheduled for Monday, May 22, 2017 and features 4 leading health economists (2 who have advised Democrats and 2 who have counseled Republicans) to discuss key topical health policy issues facing the United States and the world. Plenary speakers include:
  • Moderator: Peter J. Neumann, ScD
  • Speaker: Joseph R. Antos, PhD, Wilson H. Taylor Scholar in Health Care and Retirement Policy, American Enterprise Institute, Washington, DC, USA
  • Speaker: David M. Cutler, PhD, Harvard College Professor, Otto Eckstein Professor of Applied Economics, Harvard University, Cambridge, MA, USA
  • Speaker: Jonathan Gruber, PhD, Ford Professor of Economics, Massachusetts Institute of Technology, Cambridge, MA, USA
  • Speaker: Gail R. Wilensky, PhD, Economist and Senior Fellow, Project HOPE, Baltimore, MD, USA
The second plenary, Social Network Interventions and Population Health, features the work of Dr. Nicholas Christakis who will review recent research from his lab describing two classes of social network interventions—involving both offline and online networks—that can help make the world better. He will also discuss how by understanding social influence, it is possible to intervene in social systems to make improvements in diverse arenas such as health, wealth, cooperation, coordination, and learning. Speakers include: The third plenary session, When Do We Really Need Randomized Controlled Trials?, will address how big data is changing the strength of evidence in observational studies and how this is influencing the types of studies where randomization is necessary. Speakers include:
  • Moderator: William H. Crown, PhD
  • Speaker: Steven Goodman, MD, MHS, PhD, Associate Dean of Clinical and Translational Research and Professor of Medicine and Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
  • Speaker: Sebastian Schneeweiss, MD, ScD, Professor of Medicine, Harvard Medical School and Vice Chief, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
  • Speaker: Robert M. Califf, MD, Donald F. Fortin, MD Professor of Cardiology, School of Medicine, Duke University, Durham, NC, USA (invited)
ISPOR is recognized globally as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in health care decision making. The ISPOR 22nd Annual International Meeting is expected to draw more than 4,000 health care stakeholders with an interest in HEOR, including policy makers, payers, thought leaders, researchers, academicians, decision makers, and patient representatives. The conference also features the Society’s renowned Essential HEOR Education curriculum of half-day and full-day short courses on May 20-21, 2017. The ISPOR Short Course Program offers 30+ HEOR course topics across 7 tracks. A variety of issue panels, workshops, forums, educational symposia, podium presentations, and poster presentations will also be featured. Additional information on the conference can be found at: Conference | Registration | Short Course Program |Sponsorship | Exhibits | Press

###

   

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×